JP2021534244A5 - - Google Patents

Info

Publication number
JP2021534244A5
JP2021534244A5 JP2021531626A JP2021531626A JP2021534244A5 JP 2021534244 A5 JP2021534244 A5 JP 2021534244A5 JP 2021531626 A JP2021531626 A JP 2021531626A JP 2021531626 A JP2021531626 A JP 2021531626A JP 2021534244 A5 JP2021534244 A5 JP 2021534244A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
disease
disorders
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531626A
Other languages
English (en)
Japanese (ja)
Other versions
JP7591500B2 (ja
JP2021534244A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046182 external-priority patent/WO2020033955A1/en
Publication of JP2021534244A publication Critical patent/JP2021534244A/ja
Publication of JP2021534244A5 publication Critical patent/JP2021534244A5/ja
Priority to JP2024200937A priority Critical patent/JP2025037892A/ja
Application granted granted Critical
Publication of JP7591500B2 publication Critical patent/JP7591500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531626A 2018-08-10 2019-08-12 ピロロピリミジンitk阻害剤 Active JP7591500B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024200937A JP2025037892A (ja) 2018-08-10 2024-11-18 ピロロピリミジンitk阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717400P 2018-08-10 2018-08-10
US62/717,400 2018-08-10
PCT/US2019/046182 WO2020033955A1 (en) 2018-08-10 2019-08-12 Pyrrolopyrimidine itk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024200937A Division JP2025037892A (ja) 2018-08-10 2024-11-18 ピロロピリミジンitk阻害剤

Publications (3)

Publication Number Publication Date
JP2021534244A JP2021534244A (ja) 2021-12-09
JP2021534244A5 true JP2021534244A5 (cg-RX-API-DMAC7.html) 2022-08-29
JP7591500B2 JP7591500B2 (ja) 2024-11-28

Family

ID=69405523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531626A Active JP7591500B2 (ja) 2018-08-10 2019-08-12 ピロロピリミジンitk阻害剤
JP2024200937A Withdrawn JP2025037892A (ja) 2018-08-10 2024-11-18 ピロロピリミジンitk阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024200937A Withdrawn JP2025037892A (ja) 2018-08-10 2024-11-18 ピロロピリミジンitk阻害剤

Country Status (13)

Country Link
US (4) US11021482B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833350A4 (cg-RX-API-DMAC7.html)
JP (2) JP7591500B2 (cg-RX-API-DMAC7.html)
KR (1) KR102849047B1 (cg-RX-API-DMAC7.html)
CN (2) CN112823005B (cg-RX-API-DMAC7.html)
AU (1) AU2019317625B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002479A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109192A1 (cg-RX-API-DMAC7.html)
IL (1) IL280593A (cg-RX-API-DMAC7.html)
MX (1) MX2021001558A (cg-RX-API-DMAC7.html)
PH (1) PH12021550187A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100525SA (cg-RX-API-DMAC7.html)
WO (1) WO2020033955A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) * 2018-08-10 2024-11-28 アクラリス セラピューティクス,インコーポレイテッド ピロロピリミジンitk阻害剤
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
PH12021552036A1 (en) 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 腸道選擇性jak3抑制劑的投與
KR102560138B1 (ko) * 2020-06-15 2023-07-27 경북대학교 산학협력단 신경교세포 표현형 기반의 siRNA 다중 스크리닝을 통해 선별된 신경교세포 인산화효소의 신경염증 조절 용도
CN114887080B (zh) * 2020-12-08 2023-10-31 深圳瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
KR20230019801A (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN113571191A (zh) * 2021-08-31 2021-10-29 复旦大学附属中山医院 免疫检查点抑制剂相关mace发生风险的预测方法
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
EP4615440A1 (en) * 2022-11-08 2025-09-17 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of itk mediated conditions
CN116115760A (zh) * 2022-12-15 2023-05-16 浙江大学 Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
AU2024415240A1 (en) * 2023-12-28 2026-07-30 Aclaris Therapeutics, Inc. Crystalline polymorph of an itk inhibitor
AU2024415877A1 (en) * 2023-12-28 2026-07-30 Aclaris Therapeutics, Inc. Methods of synthesizing substituted pyrrolopyrimidine compounds
CN117982685B (zh) * 2024-01-26 2025-05-30 北京大学人民医院 用于骨肉瘤检测的光学分子成像探针及其制备方法和应用
WO2025181247A1 (en) * 2024-02-28 2025-09-04 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2025235366A1 (en) * 2024-05-07 2025-11-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of atopic dermatitis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277954A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー ヒューズ インスティテュート Jak−3インヒビターを用いたc−jun発現の阻害方法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ3阻害剤
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100105661A1 (en) 2007-01-12 2010-04-29 Astellas Pharma Inc. Condensed pyridine compound
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CA2984183C (en) 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
US10159662B2 (en) 2015-12-11 2018-12-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
RU2714206C1 (ru) 2016-06-30 2020-02-13 Даевунг Фармасьютикал Ко., Лтд. Пиразолопиримидиновые производные в качестве ингибитора киназы
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) * 2018-08-10 2024-11-28 アクラリス セラピューティクス,インコーポレイテッド ピロロピリミジンitk阻害剤
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021552036A1 (en) 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
WO2021022178A1 (en) 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors

Similar Documents

Publication Publication Date Title
JP2022531088A5 (cg-RX-API-DMAC7.html)
JP2022542434A5 (cg-RX-API-DMAC7.html)
JP7010935B2 (ja) Usp30の阻害剤としての活性を有するシアノ置換ヘテロ環
AU2017378943B2 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
AU2022412827A1 (en) Heterocyclic compound having anti-tumor activity and use thereof
AU2019323035B2 (en) Pyrazine compounds and uses thereof
AU2015304883B2 (en) Aminopyrimidinyl compounds as JAK inhibitors
ES2704024T3 (es) Moduladores P2X7
AU2010313401B2 (en) Pyrimidine compounds as delta opioid receptor modulators
CN119119039A (zh) 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
AU2017217542A1 (en) Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
CA2856505A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI851747B (zh) 介導酪氨酸激酶2活性的雜環化合物
JP6554538B2 (ja) 未分化リンパ腫キナーゼの多環状阻害剤
JP7312171B2 (ja) ピラゾロピリジノン化合物
KR102723359B1 (ko) 피라졸로피리디논 화합물
JP7261752B2 (ja) 新規キノリノン化合物
KR20240150493A (ko) 화합물 및 그 용도
EP4320103A1 (en) Pyrimidine based ras modulators and uses thereof
CN113439080B (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
WO2023001247A1 (zh) 哒嗪酮类化合物
US10172856B2 (en) 2,4-diaminopyrimidine derivatives as histamine H4 modulators
IL325314A (en) Tyk2 inhibitors, compositions and methods thereof
CN114075196B (zh) 一类芳香环并内酰胺类化合物、其制备方法和用途
TWI896831B (zh) 一種作為pak4激酶抑制劑的化合物及其製備方法和應用